• Featured Product
  • KD/KO Validated

FABP4 Polyklonaler Antikörper

FABP4 Polyklonal Antikörper für WB, IHC, IF/ICC, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, IF/ICC, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 12802-1-PBS

Synonyme

Adipocyte lipid-binding protein, Adipocyte-type fatty acid-binding protein, AFABP, ALBP, Fatty acid binding protein 4



Geprüfte Anwendungen

Produktinformation

12802-1-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA FABP4 und zeigt Reaktivität mit human, Maus, Ratten

Getestete Reaktivität human, Maus, Ratte
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen FABP4 fusion protein Ag3912
Vollständiger Name fatty acid binding protein 4, adipocyte
Berechnetes Molekulargewicht 132 aa, 15 kDa
Beobachtetes Molekulargewicht 15 kDa
GenBank-ZugangsnummerBC003672
Gene symbol FABP4
Gene ID (NCBI) 2167
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.